Linker Information

General Information of This Linker

Linker ID	LIN0ZQDJX
Linker Name	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
Linker Type	Flexible dual-reactive (amino/thiol) linker; Thiol-sensitive linker
Antibody-Linker Relation	Cleavable
Structure
Structure	3D MOL		2D MOL
Formula	C12H12N2O4S2
Isosmiles	C1CC(=O)N(C1=O)OC(=O)CCSSC2=CC=CC=N2
PubChem CID	100682
InChI	InChI=1S/C12H12N2O4S2/c15-10-4-5-11(16)14(10)18-12(17)6-8-19-20-9-3-1-2-7-13-9/h1-3,7H,4-6,8H2
InChIKey	JWDFQMWEFLOOED-UHFFFAOYSA-N
IUPAC Name	(2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate
Pharmaceutical Properties	Molecule Weight	312.4	Polar area	127
	Complexity	376	xlogp Value	0.7
	Heavy Count	20	Rot Bonds	7
	Hbond acc	7	Hbond Donor	0

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

Quinoin cetuximab immunoconjugate [Investigative]

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27.70 nM	Positive EGFR expression (EGFR +++/++)
Method Description	Cells were treated with different concentrations of drugs for 72 h. The viability was determined using the MTT assay.
In Vitro Model	Colon carcinoma	GEO cells (Cetuximab-resistant)		CVCL_0271

Y-TR1 SPDP [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35.00 ug/mL	Positive CD26 expression (CD26+++/++)
Method Description	Viability assay of Jurkat cells incubated for 72 h with ADC.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

References

Ref 1	A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins (Basel). 2023 Jan 9;15(1):57. doi: 10.3390/toxins15010057.
Ref 2	Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Cancers (Basel). 2019 Aug 8;11(8):1138. doi: 10.3390/cancers11081138.